Linkedin

Puck drop is just a short time away for two of the best teams in the league to meet in today’s national TV matinee. The Colorado Avalanche plays host to the Pittsburgh Penguins who are still in the midst of the race towards the top of the Metropolitan Division. For the burgundy and blue Avalanche team, the Mile High altitude levels hope to play to their advantage in what should be a very hard-fought game. We do have an update on Nazem Kadri, who unfortunately is out for today’s game with an upper-body injury. This comes after finishing out Thursday’s game against the San Jose Sharks after taking a hard cross-check by Timo Meier. It is expected then that Nicolas Aube-Kubel will come into the lineup after being a healthy scratch on Thursday night. For the Penguins, there was also concern about Jason Zucker who’d just returned from injury on Thursday night against the Minnesota Wild. He was injured in that game and will also be out today for the Penguins while still being evaluated. Jason Zucker is still being evaluated after leaving last game with an apparent lower-body injury. He won’t play today.— Taylor Haase (@TaylorHaasePGH) April 2, 2022…

Moscow: Russian Health Ministry has registered the nasal version of Sputnik V, the world's first nasal vaccine against COVID-19. "Russian Health Ministry registers the nasal version of Sputnik V, the world's first nasal vaccine against COVID-19," Sputnik V tweeted on late Friday. In January, the Russian news agency TASS reported that the nasal vaccine against the novel coronavirus infection will be in civil circulation and available for Russians within three to four months, quoting the director of the Gamaleya Centre, Alexander Gintsburg. "The nasal vaccine for the civil circulation will be available in three to four months," the Director had said. It will be efficient against the new Omicron coronavirus strain, Gintsburg said. "Laboratory tests show the Sputnik V protects against the Omicron in its ordinary injection form, and it will certainly be efficient in the nasal form," he added, according to TASS. In October last year, the Russian Ministry of Health issued the authorization to the Gamaleya Centre for the second phase of clinical trials of the coronavirus vaccine in the nasal spray form. The Sputnik V COVID-19 vaccine was administered first in India in Hyderabad in May 2021. The first consignment of 1.50 lakh doses of Sputnik-V vaccine…

Photo credit getty Building your personal brand means sharing your thought leadership with the people you seek to influence and impact. One powerful place to do that is LinkedIn. After all, when it comes to establishing discussions with other professionals, LinkedIn is a exceptional platform with nearly a billion professional members and many features you can use to expand your brand by delivering value to your target audience. To support thought leaders, LinkedIn launched “Creator Mode” about a year ago, and it has been well received by LinkedIn members. Creator Mode makes it easy for people who are checking you out to see what topics you discuss. When you have Creator Mode turned on, you can choose the hashtags with which you want to be associated, and they appear prominently on your profile, right below your headline. In just under 12 months, LinkedIn reported a nearly 50% increase in the number of people who follow those who have creator mode turned on. And they’ve made creators’ content more popular too with an almost 30% increase in the engagement on content created by those who are using this feature. Creator Mode is such a success, LinkedIn is taking it to the…

Mark Zuckerberg told the world last October that he was rebranding Facebook to Meta as the company pushes toward the metaverse.Facebook | via ReutersFacebook parent Meta has lost some of its top artificial intelligence scientists this year as the company continues its pivot toward the metaverse.At least four prominent members of Meta AI have departed in recent months, according to people familiar with the matter and LinkedIn analysis. Between them, the scientists have published dozens of academic papers in world-renowned journals and made multiple breakthroughs that Meta has used to enhance Facebook and Instagram.Karl Hermann, an AI entrepreneur who used to work at rival lab DeepMind, told CNBC on Monday the true figure could be more like half a dozen, adding that the company's London AI lab had seen an alarming number of exits. "Meta's London office just collapsed and they lost most of their researchers in the span of six weeks," he said.Neil Lawrence, professor of machine learning at the University of Cambridge, told CNBC that he wasn't surprised. "Mark's gone all Meta now ... and they never invested properly in anything in London in the first place," he said.Those who have left the company include Edward…

Published March 31, 2022 at 3:05 AM MDT Russia is pulling some troops away from Ukraine's capital. Shanghai is going through a staggered COVID lockdown. A technology used to promote misinformation online enters the business world. Copyright 2022 NPR

We've detected unusual activity from your computer network To continue, please click the box below to let us know you're not a robot.

New Delhi/Brasilia: Microsoft-owned LinkedIn has changed its global policy for job postings after Brazilian authorities flagged the removal of postings on its platform that were exclusive to black and indigenous professionals. The professional networking website faced severe criticism for excluding a job opening by the Centre for the Analysis of Freedom and Authoritarianism in Brazil. In the job posting, the Brazilian organisation expressed that preference would be given to black and indigenous candidates in the selection process, reports ZDNet. “We have updated our global job posting policy to allow publication of publications that express a preference for professionals from historically disadvantaged groups in hiring in countries where this practice is considered legal,” the company said in a statement late on Tuesday. LinkedIn’s global policy prohibits discrimination in job postings based on characteristics such as age, gender, disability, ethnicity, race, and sexual orientation. After the job vacancy was removed, the platform received severe criticisms from its Brazilian users. “In Brazil, affirmative vacancies are now allowed, including for black and indigenous people. We appreciate the feedback we have received from our community in Brazil,” said LinkedIn. LinkedIn was also notified by consumer protection agency Procon-SP, who requested the professional networking…

Microsoft-owned LinkedIn has changed its global policy for job postings after Brazilian authorities flagged the removal of postings on its platform that was exclusive to black and indigenous professionals. The professional networking website faced severe criticism for excluding a job opening by the Centre for the Analysis of Freedom and Authoritarianism in Brazil. In the job posting, the Brazilian organization expressed that preference would be given to black and indigenous candidates in the selection process, reports ZDNet. We have updated our global job posting policy to allow publication of publications that express a preference for professionals from historically disadvantaged groups in hiring in countries where this practice is considered legal – company said in a statement late on Tuesday. LinkedIn’s global policy prohibits discrimination in job postings based on characteristics such as age, gender, disability, ethnicity, race, and sexual orientation. After the job vacancy was removed, the platform received severe criticism from its Brazilian users. “In Brazil, affirmative vacancies are now allowed, including for black and indigenous people. We appreciate the feedback we have received from our community in Brazil,” said LinkedIn. LinkedIn was also notified by the consumer protection agency Procon-SP, who requested the professional networking website…

In the current era of technology one thing we always take note of is the new updates and how vastly and quickly many applications are growing. However, while every app grows and the world takes note of most of them, we miss out on one specific platform.The LinkedIn platform is a place which people around the world use a lot. However, while the job seeking is done, not all of us pay attention to how far it has come. If this particular line made you realize that LinkedIn has seen its growth over the years quite massively, we would like to tell you that the current growth it has made will blow your minds away.While the downloads during the Covid-19 times were great, the usage has massively increased this new year. The January of 2022 showed an estimated of around 710 weekly downloads. However, the past week's downloaded estimates broke all records.In the past week App figures, an app intelligence platform, showed an average of over 1.1M downloads on LinkedIn. This is probably the greatest download estimate the application has seen in its history. The best part was that the application download wasn’t limited to just the App or Play Store.…

29 March 2022 07:00 BST   Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding   Ondexxya (andexanet alfa) has been approved in Japan for patients treated with the Factor Xa (FXa) inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the  ANNEXA-4  Phase III clinical trial showing Ondexxya rapidly and markedly reversed anti-FXa activity in patients with acute major bleeding. Ondexxya is the first approved medicine in Japan to specifically reverse the anticoagulant effect of FXa inhibitors apixaban, rivaroxaban or edoxaban in patients experiencing a life-threatening or uncontrolled bleed. Japan is also the first country to provide full regulatory approval of Ondexxya for use with all three of the FXa inhibitors currently available. FXa inhibitors are increasingly used for the prevention and treatment of thrombotic events, including deep vein thrombosis and pulmonary embolism, or in patients at high risk of a stroke due to an irregular heart rate (atrial fibrillation). While they prevent unwanted clots from forming, they can also increase the risk of major bleeding, which can be life-threatening.1,2 Masahiro Yasaka, MD, PhD, National Hospital Organisation Kyushu Medical Centre, Fukuoka, Japan, said: “FXa inhibitors are essential medicines for people prone to developing blood…